Oral Androgens in Man-4: (Short Title: Oral T-4)

Completed · Phase 1/Phase 2 · Has a placebo group

Conditions studied: Contraception

In brief

The protocol was designed to address the hypothesis that oral testosterone enanthate plus dutasteride can suppress the secretion of LH and FSH after four weeks of administration. In addition, we will compare the gonadotropin suppression mediated by a dose of testosterone enanthate (400 mg twice daily) that would be expected to maintain the serum testosterone in the normal range throughout the day, with the same dose (800 mg once daily) administered once daily. This larger once-daily dose is expected to result in a higher peak and lower trough by the end of the dosing interval

Key facts

Study ID
NCT00399165
Run by
University of Washington
People needed
20
Starts
2006-11-01
Expected to finish
2007-05-01
Last updated by the study team
2008-09-22

Who can join

Age: 18 and older, up to 55. Sex: male. Healthy volunteers: accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.